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Evaluation of T1 relaxation time 
in prostate cancer and benign 
prostate tissue using a Modified 
Look-Locker inversion recovery 
sequence
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Andreas Maxeiner4, Katharina Erb-Eigner1 & Marcus R. Makowski1,5
Purpose of this study was to evaluate the diagnostic performance of T1 relaxation time (T1) for 
differentiating prostate cancer (PCa) from benign tissue as well as high- from low-grade PCa. Twenty-
three patients with suspicion for PCa were included in this prospective study. 3 T MRI including a 
Modified Look-Locker inversion recovery sequence was acquired. Subsequent targeted and systematic 
prostate biopsy served as a reference standard. T1 and apparent diffusion coefficient (ADC) value in PCa 
and reference regions without malignancy as well as high- and low-grade PCa were compared using the 
Mann-Whitney U test. The performance of T1, ADC value, and a combination of both to differentiate 
PCa and reference regions was assessed by receiver operating characteristic (ROC) analysis. T1 and ADC 
value were lower in PCa compared to reference regions in the peripheral and transition zone (p < 0.001). 
ROC analysis revealed high AUCs for T1 (0.92; 95%-CI, 0.87–0.98) and ADC value (0.97; 95%-CI, 0.94 to 
1.0) when differentiating PCa and reference regions. A combination of T1 and ADC value yielded an even 
higher AUC. The difference was statistically significant comparing it to the AUC for ADC value alone 
(p = 0.02). No significant differences were found between high- and low-grade PCa for T1 (p = 0.31) and 
ADC value (p = 0.8). T1 relaxation time differs significantly between PCa and benign prostate tissue with 
lower T1 in PCa. It could represent an imaging biomarker for PCa.
Magnetic resonance imaging (MRI) has proven its potential to detect clinically significant prostate cancer (PCa) 
with high accuracy and provide information regarding local tumor staging1–4. According to current guidelines, 
multiparametric MRI (mpMRI) combining high-resolution T2-weighted imaging (T2WI), diffusion-weighted 
imaging (DWI), and dynamic contrast-enhanced (DCE) MRI should be evaluated semi-quantitatively using the 
prostate imaging - reporting and data system (PI-RADS)5. In addition, DWI and DCE can be evaluated quanti-
tatively, and selected derived parameters have proven promising imaging biomarkers for the characterization of 
cancerous tissues within the prostate6–9.
Non-contrast-enhanced T1-weighted imaging (T1WI) currently only is used for detection of hemorrhage 
and no information regarding tumor characterization is derived from this sequence type5,10. T1 mapping enables 
the reliable evaluation of the spin-lattice relaxation time (T1) and thus provides reproducible data on intrinsic 
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tissue values11. It can be used as a fast, quantitative and noninvasive technique to determine biological tissue 
properties12. In prostate MRI, non-contrast-enhanced T1 mapping is used for computation of parametric phar-
macokinetic maps from signal-intensity curves acquired during DCE. In the context of cardiovascular imaging, 
T1 mapping has been established as an essential tool for characterization of myocardial tissue including the quan-
tification of amyloidosis and detection of inflammatory myopathy13,14. Few studies have evaluated its value for 
prostate imaging with mixed results using different technical approaches15–17.
The purpose of this explorative study was to evaluate if non-contrast-enhanced T1 relaxation time (T1) meas-
ured using a Modified Look-Locker inversion recovery sequence (MOLLI) differs between malignant prostate 
lesions and tissue not harboring malignancy as well as high- and low-grade PCa and thus could be used as an 
imaging biomarker for the detection of PCa and the prediction of tumor grading.
Material and Methods
Study population. For this prospective study 90 consecutive patients with clinical suspicion for PCa were 
screened between July 2016 and December 2018. Patients with general contraindications for MRI, for prostate 
biopsy, and patients with previously biopsy-proven PCa were excluded. Only patients who subsequently under-
went prostate biopsy at our institution were included in the final evaluation. Our institutional ethics review 
board (Ethikkommission der Charité – Universitätsmedizin Berlin) approved this study (application number 
EA1/076/16). Written informed consent was obtained from all participants. All research was performed in 
accordance with relevant guidelines/regulations.
Acquisition of MRI and T1 mapping. Before undergoing biopsy, all patients were examined with a single 
3 T MRI scanner (Magnetom Skyra, Siemens, Erlangen, Germany). Biparametric MRI including T2WI and DWI 
was performed using an imaging protocol in accordance with recommendations from current guidelines5.
Sequence parameters of axial echo-planar imaging DWI were as follows: field-of-view 220*220 mm, in-plane 
resolution 1.4*1.4 mm, slice thickness 3 mm, no gap, 23 slices, repetition time (TR) 4,400 ms, echo time (TE) 
61 ms, measured b-values of 50, 100, 500, and 1,000 s/mm2, total acquisition time 5 min 5 s. ADC maps were cal-
culated based on b-values of 50 and 1,000 s/mm2 and images with a b-value of 1,400 s/mm2 were also calculated by 
the software preinstalled on the MRI scanner (software version VE11A). For T1 mapping MOLLI was used11. In 
this sequence, radio frequency pulses are applied to cause an inversion of the protons’ spins. Within defined time 
intervals (inversion time), serial T1WI is acquired. Images were acquired sequentially for each slice and sequence 
parameters were as follows: field-of-view 281*281 mm, in-plane resolution 1.3*1.3 mm, slice thickness 3 mm, no 
gap, 20 slices, TR 808.6 ms, TE 2.45 ms, flip-angle 35°, total acquisition time 4 min 28 s. T1 maps were calculated 
by the software preinstalled on the MRI scanner (see above).
All patients were asked to empty their rectum before the examination. However, no mechanical evacuation of 
air from the rectum was performed.
Evaluation of MRI. Biparametric MRI was evaluated by an uroradiologist with more than 5 years of experi-
ence in reporting of mpMRI of the prostate and classified according to PI-RADS version 25. Suspicious or equiv-
ocal lesions (PI-RADS ≥3) were identified and marked on a standardized sector map.
Prostate biopsy. Patients included in the final evaluation underwent prostate biopsy at our institution after MRI 
in order to assure that all biopsies were performed using the same technical approach and according to the same stand-
ard. All but one patient underwent systematic transrectal ultrasound (TRUS)-guided biopsy. In patients with suspicious 
or equivocal lesions (PI-RADS ≥3) additional targeted biopsies of these lesions were acquired using an MRI/TRUS 
fusion technique already described elsewhere18. One patient with a suspicious lesion refused to undergo systematic 
transrectal biopsy and only underwent targeted direct MRI-guided in-bore biopsy of the respective lesion.
Histopathological evaluation. All biopsy cores from systematic and targeted biopsies were evaluated. 
Gleason patterns and grade groups were defined according to the recommendations of the 2014 International 
Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma19. The 
cores with the highest ISUP grade group from targeted biopsies or systematic biopsies taken from the area of a 
suspicious or equivocal lesion identified on MRI were used as a reference standard for each respective lesion.
Evaluation of T1. T1 maps were evaluated by a single uroradiologist with more than 5 years of experience in 
reporting of mpMRI of the prostate blinded to the results of biopsy using a dedicated software (Visage 7, Version 
7.1.11, Visage Imaging GmbH, Berlin, Germany). On axial imaging a circular region-of-interest (ROI) was placed 
within each suspicious or equivocal lesion previously identified on T2WI and DWI and subsequently targeted by 
biopsy. The size of each ROI was adapted to the size of the respective lesion. ROIs were placed within each lesion 
on the sequence best depicting the lesion (T2WI or DWI) and then copied to the same location on the other 
sequences including T1 maps. Manual corrections were made, if there was an obvious misalignment between the 
sequences due to patient or bowel movement or image distortion occurring on DWI. Within these ROIs mean T1 
(ms) and apparent diffusion coefficient (ADC) value (mm2/s) were measured.
In addition, mean T1 and ADC value were measured within circular ROIs with a minimum size of 50 mm2 in the 
peripheral zone (PZ) and transition zone (TZ) in areas not suspicious on biparametric MRI (PI-RADS score <3) at 
the level of the apex, the midgland, and the base on both sides of each patient’s prostate who had undergone system-
atic biopsy. Measurements within these ROIs served as a reference for non-cancerous tissue. Measurements in areas 
surrounding suspicious or equivocal lesions identified on MRI or in areas with biopsy-proven PCa on systematic 
biopsy without a corresponding lesion on MRI were omitted. For exemplary placement of ROIs see Fig. 1.
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Statistical evaluation. T1 and ADC value of suspicious or equivocal lesions identified on biparametric 
MRI (PI-RADS score ≥3; lesions) were compared to T1 and ADC value of regions not suspicious on biparametric 
MRI (PI-RADS score <3) without corresponding biopsy-proven PCa on systematic biopsy (reference regions). 
Regions that yielded PCa on systematic biopsy whilst not being suspicious on biparametric MRI (PI-RADS score 
<3) were excluded from further evaluation. This was done as due to the lack of a circumscribed lesion on imaging 
and the impossibility to exactly define the location from which the respective biopsy core was taken during sys-
tematic biopsy, it would not have been possible to ensure that T1 and ADC value measured within a ROI would 
have been representing the biopsy-proven PCa or surrounding benign tissue. In the one patient who only under-
went targeted direct MRI-guided in-bore biopsy only measurements within the target lesion were performed.
In addition, T1 and ADC value of suspicious or equivocal lesions identified on biparametric MRI (PI-RADS 
score ≥3) with biopsy-proven PCa (PCa lesions) were compared to T1 and ADC value of regions not suspicious 
on biparametric MRI (PI-RADS score <3) without corresponding biopsy-proven PCa on systematic biopsy (ref-
erence regions). As a result, suspicious or equivocal lesions on biparametric MRI (PI-RADS score ≥3) without 
corresponding biopsy-proven PCa were excluded from any further evaluation to exclude PCa potentially missed 
by targeted biopsy.
In order to evaluate differences in T1 and ADC value between clinically significant and not clinically signifi-
cant PCa, PCa lesions were grouped into lesions with an ISUP grade group ≥3 (considered clinically significant) 
as well as lesions with an ISUP grade group <3 (considered not clinically significant). Based on the Shapiro-Wilk 
test non-normal distribution of the data was assumed. Therefore, statistical analysis was performed with the 
package ‘clusrank’ for R 3.5.1 (Foundation for Statistical Computing, Vienna, Austria, 2018, http://www.R-project.
org) using the Mann-Whitney U test with correction for clustered data (patients) according to Rosner et al.20. A 
two-sided p-value ≤ 0.05 was considered statistically significant.
Receiver operating characteristic (ROC) analysis to assess the performance of T1 and ADC value to differenti-
ate between PCa lesions and reference regions was performed using the nonparametric (empirical) approach for 
clustered data by Obuchowski et al.21. Calculations were performed using the script ‘funcs_clusteredROC.R’ for R 
developed by the Lerner Research Institute (Cleveland Clinic, Cleveland, OH, USA) and made publicly available 
by the developers (https://www.lerner.ccf.org/qhs/software/lib/funcs_clusteredROC.R). The resulting areas under 
the curve (AUC) were compared using the method by Obuchowski et al. Cut-off analysis was done using Youden’s 
Index22. In addition, ROC analysis was performed using binarized data for T1 and ADC value (low versus high T1 
and ADC value based on the optimal cut-offs) as well as a combination of T1 and ADC value (T1 and ADC value 
both low, T1 or ADC value low, T1 and ADC value high).
ROC curves were generated using SPSS Version 22 (IBM, Chicago, IL, USA).
Results
Out of 90 patients screened for this study 23 patients subsequently underwent biopsy of the prostate at our 
institution and were included in the final evaluation. Median age was 71 years (range, 55 to 79 years), median 
prostate-specific antigen (PSA) was 6.98 ng/ml (range, 3.54 to 18.6 ng/ml). On biparametric MRI the most sus-
picious lesion was a PI-RADS 5 lesion in 8 patients, a PI-RADS 4 lesion in 9 patients and a PI-RADS 3 lesion in 
1 patient. PI-RADS 2 lesions were seen in 5 patients. In 3 of the patients with a suspicious or equivocal lesion an 
Figure 1. Exemplary images depicting placement of ROIs in a PI-RADS 4 lesion in the PZ (marked by asterisk) 
as well as contralateral reference regions in the PZ and TZ at the level of the base of the prostate (marked by 
octothorpes) on (a) the ADC map and (b) the color-coded T1 map with red representing a high T1 and blue 
representing a low T1 in a 64-year-old patient. Targeted biopsy of the PI-RADS 4 lesion yielded ISUP grade 
group 2 PCa whilst systematic biopsy yielded no PCa in the contralateral reference regions.
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additional suspicious or equivocal lesion was identified on biparametric MRI (a PI-RADS 5 lesion in 2 patients 
and a PI-RADS 4 lesion in 1 patient).
Of the 21 suspicious or equivocal lesions (PI-RADS ≥3) 15 were located in the PZ and 6 were located in the 
TZ. Median time between MRI and biopsy was 43 days (range, 2 to 188 days). In patients with suspicious or 
equivocal lesions (PI-RADS ≥3) who underwent systematic TRUS biopsy plus additional targeted biopsies of 
these lesions median time between MRI and biopsy was 44 days (range, 2 to 79 days). A median number of 2 
targeted biopsy cores were taken from each suspicious or equivocal lesion (range, 2 to 5). In one patient with a 
PI-RADS 4 lesion targeted MRI/TRUS fusion biopsy did not yield PCa. Due to the high suspicion for PCa on 
biparametric MRI an additional direct MRI-guided in-bore biopsy was performed and yielded PCa previously 
missed by MRI/TRUS fusion biopsy.
In total, in 17 out of 21 suspicious or equivocal lesions targeted biopsy yielded PCa (PCa lesions). Median 
lesion diameter of PCa lesions was 16 mm (range, 6 to 25 mm) and median lesion diameter of lesions that did not 
yield PCa was 9 mm (range, 7 to 24 mm). Nine lesions were ISUP grade group 1 PCa, 5 lesions were ISUP grade 
group 2 PCa, and 3 lesions were ISUP grade group 4 PCa. 4 out of 21 suspicious or equivocal lesions did not yield 
PCa in biopsy.
In 5 patients systematic biopsy yielded ISUP grade group 1 PCa in areas not suspicious on biparametric MRI. 
These areas were excluded from further evaluation and not used as reference regions. A total of 212 reference 
regions were included of which 106 were located in the PZ and 106 were located in the TZ.
For median T1 and ADC value in lesions, PCa lesions, and reference regions please see Tables 1 and 2. T1 and 
ADC value were significantly lower in reference regions in the TZ compared to the PZ (p < 0.001). T1 and ADC 
value of lesions and PCa lesions were significantly lower than T1 and ADC value of reference regions in the whole 
prostate (PZ and TZ combined, p < 0.001) and T1 and ADC value of lesions and PCa lesions subdivided by PZ 
and TZ were significantly lower than T1 and ADC value of the corresponding reference regions (PZ or TZ, each 
p < 0.001). When comparing T1 and ADC value of PCa lesions with an ISUP grade group ≥3 (n = 3) and PCa 
lesions with an ISUP grade group <3 (n = 14), no statistically significant differences were found (T1, p = 0.31; 
ADC, p = 0.8). For T1 and ADC values of PCa lesions within different ISUP grade groups please see Table 3.
ROC analysis showed high AUCs for T1 (0.92; 95%-confidence interval [95%-CI], 0.87–0.98) and ADC value 
(0.97; 95%-CI, 0.94 to 1.0) when differentiating PCa lesions and reference regions in the whole prostate (PZ and 
TZ; see Fig. 2), and this AUC was significantly higher for ADC value than for T1 (AUC, 0.97 versus 0.92; 95%-CI 
of the AUC difference, 0.005 to 0.09; p = 0.03). AUCs for T1 and ADC value were even higher when differentiat-
ing PCa lesions in PZ and TZ from reference regions in the PZ and TZ separately and were significantly different 
in the PZ (PZ: T1: 0.95; 95%-CI, 0.91–0.99; ADC value: 0.99; 95%-CI, 0.98–1.0; p = 0.03; TZ: T1: 0.97; 95%-CI, 
0.93–1.0; ADC value: 1.0; 95%-CI, 1.0–1.0; p = 0.25). For optimal cut-off values for T1 and ADC value and result-
ing sensitivities and specificities for the whole prostate please see Table 4.
Using binarized data for T1 and ADC value when differentiating PCa lesions and reference regions in the 
whole prostate ROC analysis also revealed high AUCs for T1 (0.89; 95%-CI, 0.79–0.98) and ADC value (0.92; 
95%-CI, 0.85–0.99) with a combination of T1 and ADC value showing an even higher AUC of 0.95 (95%-CI, 
0.88–1.0). Comparing AUCs for ADC value and a combination of T1 and ADC value statistically significant 
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Table 1. T1 and ADC value in lesions and PCa lesions. T1 and ADC value of lesions (lesions with PI-RADS ≥3) 
and PCa lesions (lesions with PI-RADS ≥3 and biopsy-proven PCa) in the whole prostate, peripheral zone, 
and transition zone. ADC, apparent diffusion coefficient; PCa, prostate cancer; PZ, peripheral zone; T1, T1 
relaxation time; TZ, transition zone.
PZ (reference regions; n = 106) TZ (reference regions; n = 106))
T1 in ms; median 
(range)
ADC values in mm2/s; 
median (range)
T1 in ms; median 
(range)
ADC values in mm2/s; 
median (range)
Base 1,666 (1,222–2,343) 1,502 (1,084–1,979) 1,486 (1,301–1,757) 1,190 (851–1,560)
Midgland 1,756 (1,488–2,412) 1,586 (1,192–1,957) 1,503 (1,343–1,799) 1,161 (919–1,451)
Apex 1,759 (1,083–2,351) 1,569 (1,076–1,976) 1,508 (1,037–1,756) 1,261 (914–1,811)
Table 2. T1 and ADC value in reference regions. T1 and ADC value of reference regions (PI-RADS <3 and 
negative histopathology) in the peripheral zone and transition zone. ADC, apparent diffusion coefficient; PZ, 
peripheral zone; T1, T1 relaxation time; TZ, transition zone.
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differences were found (0.92 versus 0.95, p = 0.02) whilst comparing T1 and a combination of T1 and ADC value 
no statistically significant differences were found (0.89 versus 0.95, p = 0.07).
Discussion
T1 was significantly lower in lesions and PCa lesions compared to reference regions in the PZ and TZ of the 
prostate (p < 0.001, respectively). However, no statistically significant differences for T1 and ADC value could be 
shown between high- and low-grade PCa.
PI-RADS is a structured reporting system for prostate mpMRI based on the semi-quantitative evaluation of 
T2WI, DWI, and DCE MRI5. One of the major limitations of PI-RADS is its limited interreader agreement, even 
between experienced readers23. The quantitative evaluation of MRI sequences as imaging biomarkers as well as 
the use of predefined cut-off values could help to overcome the limitation of a limited interreader agreement 
and also help to predict tumor grading. The value of the ADC value24–27 as well as of several parameters derived 
from DCE MRI8,9,28 has been demonstrated in several studies. However, a quantitative evaluation of these MRI 
sequences is currently not part of PI-RADS5.
ISUP grade group 1 (n = 9) ISUP grade group 2 (n = 5) ISUP grade group 4 (n = 3)
T1 in ms; median 
(range)
ADC value in mm2/s; 
median (range)
T1 in ms; median 
(range)
ADC value in mm2/s; 
median (range)
T1 in ms; median 
(range)
ADC value in mm2/s; 
median (range)
1,336 (1,238–1,532) 955 (580–1,195) 1,199 (1,037–1,341) 689 (587–930) 1,247 (1,223–1,344) 789 (715–1,056)
Table 3. T1 and ADC value in PCa lesions separated by ISUP grade groups. T1 and ADC value of PCa lesions 
(lesions with PI-RADS ≥3 and biopsy-proven PCa) separated by ISUP grade groups. ADC, apparent diffusion 
coefficient; ISUP, International Society of Urological Pathology; PCa, prostate cancer; T1, T1 relaxation time.
Figure 2. ROC curves for T1 and ADC value when differentiating PCa lesions and reference regions in the 
whole prostate (PZ and TZ combined).





T1 ≤1,345 ms 14 3 201 11 82% (57–96%) 95% (91–97%)
ADC value ≤1,078 mm2/s 16 1 192 20 94% (71–100%) 90% (85–94%)
T1 or ADC value see above 16 1 185 27 94% (71–100%) 87% (82–91%)
T1 and ADC value see above 14 3 208 4 82% (57–96%) 98% (95–100%)
Table 4. Optimal cut-offs for T1 and ADC values. Optimal cut-offs as well as resulting sensitivities and 
specificities for T1 and ADC values to differentiate 17 PCa lesions and 212 reference regions (4 lesions with 
discordant findings on MRI and biopsy were excluded). Sensitivity and specificity of a combination of binarized 
T1 and ADC value are also given – rating either a low T1 or ADC value or only the combination of both low 
values for both parameters as positive. ADC, apparent diffusion coefficient; CI, confidence interval; T1, T1 
relaxation time; TP, true positives; FN, false negatives; TN, true negatives; FP, false positives.
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The evaluation of prostate tissue on T2WI is an integral part of PI-RADS5. Applying the technical specifica-
tions for sequence acquisition of PI-RADS T2WI is acquired in a way that it cannot be evaluated quantitatively. 
However, in selected studies T2 relaxation time has been shown to differ significantly between malignant and 
benign prostate lesions as well as high- and low-grade PCa and therefore represents an imaging biomarker that is 
able to detect PCa and help predict its grading29–31. T1WI currently only plays a minor role in the interpretation of 
prostate mpMRI. It is used primarily to detect hemorrhage within the prostate and seminal vesicles. No relevant 
information regarding tumor characterization is derived from this sequence type. T1 mapping is an emerging 
quantitative diagnostic tool in the field of MRI that enables the direct visualization and quantification of the T1 of 
tissues. To generate a T1 map, proton spin-lattice relaxation times are calculated for each voxel using multiple raw 
images with different degrees of recovery of longitudinal or spin-lattice magnetization.
Currently, in prostate MRI non-contrast-enhanced T1 mapping is most frequently used for computation of 
parametric pharmacokinetic maps from signal-intensity curves acquired during DCE MRI. Techniques using at 
least two acquisitions with different flip angles are commonly used for this purpose32 but other techniques have 
also been evaluated in order to further optimize the accuracy of T1 mapping33. Furthermore, pathological tissue 
alterations as a result of disease processes such as extracellular matrix expression and tissue fibrosis can be nonin-
vasively visualized and quantified based on changes in T1 relaxation properties13,14,34,35. Few studies have already 
evaluated non-contrast-enhanced T1 mapping for the diagnosis of PCa using different technical approaches. In 
1987, Kjaer et al. were not able to detect significant differences in T1 between PCa and benign prostate hyperpla-
sia in 18 patients using six inversion recovery sequences with a fixed TR and different inversion times (TI) and a 
1.5 T magnet15. Foltz et al. found significantly shorter T1 in PCa lesions compared to normal appearing prostate 
tissue in 13 patients using a magnetization-prepared spiral technique and a 1.5 T magnet16. More recently, Ma et 
al. used MR fingerprinting36 and a 3 T magnet to quantitatively measure T1 on non-contrast-enhanced MRI in 
109 PCa lesions and normal appearing prostate tissue in the PZ17. They found T1 to differ significantly between 
PCa and normal appearing prostate tissue but failed to show significant differences between high- and low-grade 
PCa. However, they only evaluated lesions and reference regions in the PZ. Their results for the PZ are in line 
with our results, with overall shorter T1 in our study in PCa lesions (1,301 ms compared to 1,628 ms) as well as in 
reference regions (1,756 ms at the level of the midgland compared to 2,247 ms)17.
The inversion recovery based modified Look-Locker imaging sequence (MOLLI) is currently the most widely 
used and among the best validated sequences for T1 mapping11. It has been used in DCE MRI as a T1 mapping 
technique for computation of parametric pharmacokinetic maps and has proven an accuracy and repeatability 
rated clinically acceptable in phantom studies37. To our best knowledge, any further use of MOLLI for prostate 
imaging has not been reported yet. T1 measured with MOLLI has proven to be a robust imaging biomarker in car-
diac MRI13,14 as well as selected malignancies such as renal cell cancer with an excellent interreader agreement35.
In this explorative study we evaluated T1 measured on non-contrast-enhanced MRI using MOLLI as an imag-
ing biomarker for PCa. We were able to show that T1 and ADC value of the PZ and TZ differ significantly from 
each other and that they differ from T1 and ADC value of PCa in either zone. This allowed to distinguish PCa 
lesions from reference regions in the prostate with high AUCs, sensitivity, and specificity. A combination of T1 
and ADC value yielded an even higher AUC compared to the AUCs of T1 and ADC value alone. This difference 
was found to be statistically significant when comparing a combination of T1 and ADC value with ADC value 
(p = 0.02). However, due to the explorative character of the current analysis, sensitivity and specificity should be 
regarded with caution as the underlying cut-off values are optimized for the present patient sample. Therefore, 
cut-off values are potentially biased, and sensitivity and specificity may be overestimated. We were not able to 
demonstrate any statistically significant differences between T1 and ADC value in high- and low-grade PCa. 
Other studies have shown that ADC values do differ statistically significantly between high- and low-grade PCa24–
27. Such differences might have simply been underestimated in our study due to the small number of included PCa 
lesions as well as the small number of high-grade PCa lesions (n = 3). However, in line with our results Yu et al. 
were also not able to demonstrate differences in T1 between high- and low-grade PCa using a different technique 
for mapping17.
The small number of patients and PCa lesions included is a major limitation of this explorative study. A fur-
ther limitation is that target lesions for biopsy and evaluation of T1 were previously identified based on T2WI and 
DWI using PI-RADS version 2. Therefore, no statement can be made about the performance of T1 in PCa occult 
or presenting with only minimal signal changes on T2WI or DWI as well as the dependence or independence of 
T1 from signal alterations on T2WI and DWI. Furthermore, not all biopsies of equivocal or suspicious lesions 
on biparametric MRI yielded PCa and this could have been due to the absence of PCa. On the other hand, PCa 
might have been missed by targeted biopsy. Therefore, further evaluations focused on PCa lesions. This has led to 
a selection bias potentially overestimating the value of T1. However, inclusion of the abovementioned lesions as 
benign tissues could also have led to a bias due to PCa lesions missed by targeted biopsy, as illustrated by one of 
the patients included in this study where initial targeted MRI/TRUS fusion biopsy missed the correct diagnosis 
and only subsequent targeted direct MRI-guided in-bore biopsy yielded PCa. In order to evaluate the value of 
T1 independently from other MRI sequences ideally whole-mount prostatectomy specimens should be used as 
a reference standard. Finally, the histopathological changes that result in the observed differences in T1 in PCa 
lesions and reference regions currently remain unclear.
In conclusion, in this explorative study T1 mapping using MOLLI was able to differentiate PCa lesions from 
prostatic reference regions not harboring malignancy with lower T1 in PCa lesions. Further evaluation in larger 
patient cohorts is necessary in order to confirm our results, evaluate if T1 determined by MOLLI allows to differ-
entiate between malignant and benign lesions as well as high- and low-grade PCa, and provides added value to 
the sequences routinely used for prostate MRI.
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The datasets generated and analyzed during the current study are available from the corresponding author on 
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